The Q3 earnings season has got off to an uninspiring start but that doesn't mean there's not value out there. Chief among these prospective climbers are emerging markets and China whose long-term prospects remain good despite their current travails. The US biotechnology sector is another hot tip – a political and media campaign to impose drug price caps is unlikely to succeed.
from Peter Garnry - Authored content http://ift.tt/1RHrdRx
via IFTTT
Earnings Season: Slowing China and US biotech bears
ad
Enregistrer un commentaire